FibroGen’s Duchenne drug misses mark in first large trial

FibroGen’s Duchenne drug misses mark in first large trial

Source: 
BioPharma Dive
snippet: 

FibroGen once again has disappointing news to share from a clinical trial, this time from a study of an experimental treatment for Duchenne muscular dystrophy.